Skip to content

Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public

Intersection · Evidence × open label

Evidence topics tagged open label

Topics in Evidence carrying the tag open label. Unblinded design and the biases it admits.

19 topics

Topic	Participants	Replies	Views	Activity
What a statistical analysis plan adds that the paper does not open label discontinuation & dropout randomised trial surrogate endpoints Solved What a statistical analysis plan adds that the paper does not — that is the question, and I have not found it answered plainly anywhere I have looked. Statistical analysis plan, and specifically the version…		2	6.6k	10h
Second pass at: Reading a trial's population section before its results open label intention to treat estimand surrogate endpoints Solved Second pass at: Reading a trial's population section before its results Writing it up because I had to work it out twice and would rather nobody else did. Reading STEP 1 ( N Engl J Med , 2021) for the…		4	9.5k	10h
Primary endpoint hierarchies and why order matters — one year on surrogate endpoints discontinuation & dropout estimand randomised trial Solved On the subject in the title: Primary endpoint hierarchies and why order matters — one year on Working notes rather than a conclusion. A follow-up question about Primary endpoint hierarchies that I did not…	+56	61	37k	11h
Composite endpoints and the component doing the work randomised trial surrogate endpoints open label discontinuation & dropout Solved Under review Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. Collecting what is known about composite endpoints in one place, because…	+3	7	33k	13h
Interim analyses and stopping rules intention to treat surrogate endpoints open label discontinuation & dropout Interim analyses and stopping rules Writing it up because I had to work it out twice and would rather nobody else did. Asking about interim analyses and stopping rules on behalf of the question I keep seeing…	+25	29	35k	16d
Revisiting: Primary endpoint hierarchies and why order matters estimand surrogate endpoints discontinuation & dropout intention to treat Posting this under the heading it deserves: Revisiting: Primary endpoint hierarchies and why order matters Everything below is what sits behind that. I was wrong about Primary endpoint hierarchies in a thread…	+21	25	46k	3mo
Subgroup analyses: pre-specified versus discovered — a second dataset open label discontinuation & dropout estimand randomised trial On the subject in the title: Subgroup analyses: pre-specified versus discovered — a second dataset Working notes rather than a conclusion. Posting a small dataset on Subgroup analyses. It is mine, it is…	+71	79	906	3mo
Follow-up: What a statistical analysis plan adds that the paper does not randomised trial estimand open label surrogate endpoints What a statistical analysis plan adds that the paper does not I have a specific reason for asking rather than idle curiosity, and the context is below. A follow-up question about statistical analysis plan…		2	7.2k	3mo
[2026 update] Reading a supplementary appendix and finding the interesting part estimand intention to treat open label surrogate endpoints On the subject in the title: Reading a supplementary appendix and finding the interesting part Working notes rather than a conclusion. Collecting what is known about Reading a supplementary appendix in one…	+39	44	8.2k	5mo
Non-inferiority margins: how they are chosen and how they are abused open label surrogate endpoints estimand intention to treat Posting this under the heading it deserves: Non-inferiority margins: how they are chosen and how they are abused Everything below is what sits behind that. A question about non-inferiority margins that I…	+42	46	10k	5mo
Trial registration and comparing the protocol with the paper randomised trial open label intention to treat Trial registration and comparing the protocol with the paper — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin trial registration down and I want to…	+38	44	4.8k	10mo
Coming back to: Sample size calculations, read backwards from the published number estimand discontinuation & dropout surrogate endpoints randomised trial On the subject in the title: Sample size calculations, read backwards from the published number Working notes rather than a conclusion. Sample size calculations — I have the observation and I do not trust my…	+82	88	1.8k	11mo
Comparators chosen for regulatory reasons rather than clinical ones — one year on randomised trial intention to treat open label estimand Solved Comparators chosen for regulatory reasons rather than clinical ones — one year on — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Comparators chosen for…	+82	87	1.1k	12mo
Interim analyses and stopping rules — does this still hold? estimand discontinuation & dropout open label surrogate endpoints Solved Interim analyses and stopping rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Interim analyses and stopping rules, from the point of view…	+30	34	29k	13mo
Second pass at: Trial registration and comparing the protocol with the paper estimand discontinuation & dropout randomised trial open label Posting this under the heading it deserves: Second pass at: Trial registration and comparing the protocol with the paper Everything below is what sits behind that. Two things I would like separated before…	+30	34	33k	13mo
Reading a trial's population section before its results — does this still hold? randomised trial open label intention to treat discontinuation & dropout Closed Reading a trial's population section before its results — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Reading STEP 1 ( N Engl J Med , 2021)…	+140	154	5.4k	14mo
Comparators chosen for regulatory reasons rather than clinical ones surrogate endpoints open label estimand randomised trial Pinned Closed On the subject in the title: Comparators chosen for regulatory reasons rather than clinical ones Working notes rather than a conclusion. An honest uncertainty about comparators chosen for regulatory reasons…		2	27k	14mo
Follow-up: Open-label extensions: what survives and what does not open label intention to treat surrogate endpoints estimand Solved Open-label extensions: what survives and what does not — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin Open-label extensions down and I want to set…	+22	26	397	16mo
Reading a supplementary appendix and finding the interesting part open label discontinuation & dropout intention to treat estimand Reading a supplementary appendix and finding the interesting part — setting out what I have, and where I think it stops being reliable. Collecting what is known about reading a supplementary appendix in one…	+87	92	1.1k	17mo

Sponsored PeptideMeter — peptide analytics and supplier verificationPurity analysis and structured supplier verification, published as dated records rather than scores. Referenced throughout our sourcing documentation.View analytics →